CBC Group
Portfolio: CBC Group and I-Mab Biopharma
CBC Group’s stewardship of I-Mab Biopharma brings an intensely hands-on platform-based approach to a booming China biotech space often characterized by relatively passive strategies
Chinese drug developer Everest secures $310m Series C
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.
China's CBC raises healthcare credit fund
CBC Group, a China-focused healthcare investor, has raised a $300 million credit fund that will issue financing to companies backed by royalties, revenue interests, and other cash flows.
AVCJ Awards 2019: Deal of the Year - Small Cap: AffaMed Therapeutics
CBC Group established biosimilars specialist AffaMed Therapeutics to remove uncertainties in the development process and to tap Chinese demand for affordable treatments
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing